Workflow
BOTOX
icon
搜索文档
U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
Prnewswire· 2025-06-30 20:25
IRVINE, Calif., June 30, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental premarket approval (sPMA) application for SKINVIVE by JUVÉDERM® to reduce neck lines for the improvement of neck appearance. SKINVIVE by JUVÉDERM® is currently approved in the U.S. to improve skin smoothness of the cheeks in adults over the age of 21. "SKINVIVE by JUVÉDERM® is an injectable version of hyaluron ...
AbbVie (ABBV) FY Conference Transcript
2025-06-11 00:20
AbbVie (ABBV) FY Conference June 10, 2025 11:20 AM ET Speaker0 That are bearing down in the pharmaceutical sector, drug pricing specifically. Just frame for us expectations of what you're looking for when our thirty days past the MF and EO. How have conversations with the administration been going? What's the status? And does it feel like that there's going to be a resolution anytime soon? Look I'd Speaker1 say we're very encouraged by the engagement of the administration with the industry. We didn't have t ...
3 Cheap Dividend Growth Stocks to Buy Right Now
The Motley Fool· 2025-06-04 17:50
There are many solid dividend stocks right now worth considering because they trade at modest valuations. Three stocks, in particular, have high yields, have grown their payouts, and look cheap. They are ExxonMobil (XOM 0.83%), Verizon Communications (VZ -0.59%), and AbbVie (ABBV 0.12%). 1. ExxonMobil Dividend growth stocks can be ideal long-term options for any investment portfolio. That's because they not only offer a good payout, but they may also rise over time, helping offset the negative effects of in ...
特朗普猛砍药价或令药企洗牌 花旗审视政策风险后坚定看涨再生元(REGN.US)
智通财经网· 2025-05-15 12:11
特朗普政府医药政策 - 特朗普签署"最惠国"药品定价行政令 要求美国药价与全球最低价挂钩 部分药品价格或降50%-90% [2] - 政策旨在取消中间商 推动药品直销 并阻止外国压低美国药价 [2] - 行政令威胁取消药房福利管理者(PBMs)角色 打击全球制药公司股价 [1] 花旗评级调整 - 将再生元(REGNUS)评级从"中性"上调至"买入" 目标价从600美元调至700美元 [3][4] - 将艾伯维(ABBVUS)评级从"买入"下调至"中性" 目标价从205美元降至188美元 [4][5] 再生元投资逻辑 - 眼科药物Eylea和Dupixent贡献主要现金流 政策风险敞口可控 [3] - 黑色素瘤等管线产品选择权强劲 股价已从2024年高点下跌55% [4] - 采用"深耕式"创新模式 依赖少数重磅单抗药物 技术壁垒高 [3] 艾伯维风险因素 - 产品组合多元化但面临更高政策风险 包括最惠国定价和PBM改革 [5] - Humira等核心产品受行政令影响 业绩超预期对股价推动力减弱 [4] - 后期产品管线相对薄弱 威胁其市场安全定位 [5] 行业影响 - 政策冲击欧洲药企如诺和诺德(司美格鲁肽)、葛兰素史克 [1] - 特朗普曾威胁对进口药品征收高关税 已造成行业股价压力 [1]
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
Globenewswire· 2025-05-15 04:05
– Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for ABP-450, which offers potential access to the U.S. market under a single approval for all of BOTOX’s currently approved and future therapeutic indications – – Appointed Rob Bancroft as the Company’s President and Chief Executive Officer; Mr. Bancroft also joined AEON’s Board of Directors – IR ...
Recession Worries? Here's 1 of the Best Dividend Stocks for Turbulent Times
The Motley Fool· 2025-05-11 21:00
宏观经济环境 - 摩根大通认为2025年经济衰退概率达60% 主要因贸易战和关税问题[1] - 2023年启动的牛市面临威胁 市场不确定性导致主要指数进入调整区间[1][2] - 制药股通常在市场低迷期表现优异 因其分红特性和产品必需属性[3] 艾伯维公司转型战略 - 公司过去过度依赖修美乐(Humira) 该药2019年贡献58%营收 2022年销售额达210亿美元峰值[6] - 2020年以630亿美元收购艾尔建(Allergan) 获得肉毒杆菌、乔雅登等产品线 显著降低对修美乐依赖[7][9] - 2024年再斥资190亿美元收购ImmunoGen和Cerevel 其中卵巢癌药物Elahere当年销售额4.79亿美元[10] 核心产品表现 - 自主研发产品Skyrizi和Rinvoq 2024年销售额达177亿美元 同比增长51% 超预期11%[11] - 2027年销售指引270亿美元 将超越修美乐历史峰值[11] - 2025年Q1营收增长8%至133亿美元 全年销售指引上调7%至600亿美元[13] 投资价值分析 - 季度股息1.64美元/股 年化6.56美元 远期股息收益率3.5%[14] - 分析师17家买入评级 11家持有 平均目标价较现价有11%上行空间[15] - 公司被视作对抗经济衰退的防御性标的 提供稳定增长收入[14][15]
2 High-Yield Dividend Stocks to Buy in May and Hold Forever
The Motley Fool· 2025-05-10 20:45
核心观点 - 投资股息股票时,公司的基本面运营比高股息率更重要,应选择长期表现稳定且持续增加股息的公司[1] - AbbVie和Gilead Sciences符合上述标准,具有"永久持有"特质且股息率高于标普500平均水平[2][8][13] AbbVie分析 - 公司连续53年增加股息,属于股息贵族(Dividend Kings)精英组[4] - 核心产品免疫抑制剂Skyrizi和Rinvoq销售增长超预期,2027年联合销售额指引从270亿美元上调至310亿美元[6] - 成功应对"专利悬崖",在失去Humira专利独占权后仍实现收入增长,证明业务韧性[6][7] - 产品线包含肉毒杆菌等多元化疗法,研发管线储备数十个项目支持未来增长[7][8] - 远期股息率达3.5%,显著高于标普500平均1.3%[8] Gilead Sciences分析 - HIV治疗领域领导者,一季度HIV业务收入同比增长6%达46亿美元,Biktarvy为美国最常用HIV疗法[9][10] - 新冠药物Veklury虽销售波动,但过去五年对公司整体财务形成净贡献[11] - 研发管线中超过1/3(58个项目中的超19个)聚焦肿瘤学领域,推动业务多元化[12] - 远期股息率3.2%,过去十年股息增长84%[13] - 在医疗行业的创新能力和稳固地位支撑长期表现[12]
BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project"
Prnewswire· 2025-05-02 05:00
BOTOX® Cosmetic Will Provide 250 Entrepreneurs with Access to New Resources and Opportunities and Will Award 20 Grants Worth $20,000 Each to Support Business Goals. By 2030, BOTOX® Cosmetic Pledges to Empower 50,000 Entrepreneurs, Helping to Close the Confidence Gap. IRVINE, Calif., May 1, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced BOTOX® Cosmetic's continued commitment to closing the Confidence Gap with the introduction of The Confidence Project: Empowering W ...
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
The Motley Fool· 2025-04-27 06:05
核心观点 - 在经济环境充满挑战的背景下,股息股票因其韧性和稳定回报成为投资组合的优选 [1] - 推荐四支优质股息股票:艾伯维、安进、百时美施贵宝和硕腾 [2] 艾伯维 (AbbVie) - 核心业务聚焦免疫学领域,主力产品Skyrizi和Rinvoq推动收入增长 [3] - 管理层将Skyrizi和Rinvoq的2027年收入预期上调40亿美元至超过310亿美元 [4] - 其他产品如偏头痛治疗药Qulipta和肉毒杆菌品牌Botox贡献稳定收入 [5] - 股息连续53年增长,远期股息率达3.9%,显著高于标普500平均1.3% [5] 安进 (Amgen) - 尽管减肥药MariTide二期临床试验未达预期,仍具备商业化潜力 [6] - 拥有超过10款重磅药物,哮喘药Tezspire和甲状腺眼病药Tepezza为增长引擎 [7] - 股息自2011年以来增长750%,远期收益率超3.5% [7][8] 百时美施贵宝 (Bristol Myers Squibb) - 面临Opdivo和Eliquis等核心药物专利到期挑战,但通过新药获批缓解压力 [9] - 贫血药Reblozyl和抗癌药Opdualag等新产品将驱动长期增长 [10] - 过去十年股息增长68%,当前股息率高达5.1% [11] 硕腾 (Zoetis) - 全球动保行业龙头,拥有15款年销售额超1亿美元的产品和300条产品线 [12] - 主力产品Apoquel面临竞争,但新药Solensia和Librela(治疗宠物骨关节炎疼痛)将推动增长 [13] - 过去十年股息增长500%,当前股息率1.4%但无削减风险 [14]
AbbVie(ABBV) - 2025 Q1 - Earnings Call Transcript
2025-04-26 00:14
AbbVie Inc. (NYSE:ABBV) Q1 2025 - Earnings Conference Call April 25, 2025 9:00 PM ET Company Participants Liz Shea - Senior VP, IR Rob Michael - CEO Jeff Stewart - EVP, Chief Commercial Officer Roopal Thakkar - EVP, R&D, Chief Scientific Officer Scott Reents - EVP, CFO Carrie Strom - SVP of AbbVie, and President of Global Allergan Aesthetics Conference Call Participants Chris Schott - JPMorgan Terence Flynn - Morgan Stanley Carter Gould - Cantor Courtney Breen - Bernstein Mohit Bansal - Wells Fargo Steve Sc ...